Lcr Regenerans

Phase 3Small molecule

PProbionov

Lcr Regenerans is one of 19 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vulvovaginal CandidiasisActive, not recruiting

Vulvovaginal CandidiasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Vulvovaginal Candidiasis

#DrugCompanyPhaseTrials

Lotrimin

Bayer

Approved

4 2

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

15 3

Nizoral

Terazol 3

2 5

Canesten

AAVVA Pharmaceuticals Ltd.

Approved

1 6

Peridex

MMedline Industries

Phase 2

1 7

Vaccine

Pfizer

Phase 2

1 8

Brexafemme

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Boric Acid

MMansoura University

Phase 3

1 10

Butoconazole Nitrate

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis

Completed·PProbionov·Phase 3·NCT02251093·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lcr Regenerans. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lcr Regenerans compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lcr Regenerans. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Probionov company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PProbionov

Lcr Regenerans

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vulvovaginal Candidiasis1 trial

References

Drug Info

Quick Facts

Related News